MiR-502/SET8 regulatory circuit in pathobiology of breast cancer

Cancer Letters

Volumn 376, Issue 2, 2016, Pages 259-267

  Liu, Ben ^a   Zhang, Xining ^a   Song, Fengju ^a   Zheng, Hong ^a   Zhao, Yanrui ^a   Li, Haixin ^a   Zhang, Lina ^a   Yang, Meng ^a   Zhang, Wei ^b,c   Chen, Kexin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Breast cancer; Cell cycle; Epithelial to mesenchymal transition; MiR 502; SET8

Indexed keywords

MESSENGER RNA; 3' UNTRANSLATED REGION; HISTONE LYSINE METHYLTRANSFERASE; MICRORNA; MIRN502 MICRORNA, HUMAN; SETD8 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL STUDY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIR 502 GENE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; SET8 GENE; 3' UNTRANSLATED REGION; BINDING SITE; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL MOTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR INVASION;

3' UNTRANSLATED REGIONS; BINDING SITES; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MCF-7 CELLS; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84962854725     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.008     Document Type: Article

References (47)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65:87-108.
2. Chen W., Zheng R., Zeng H., Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chin. J. Cancer 2015, 34:53.
3. Zheng R., Zeng H., Zhang S., Chen T., Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett 2016, 370:33-38.
4. Fan L., Strasser-Weippl K., Li J.J., St Louis J., Finkelstein D.M., Yu K.D., et al. Breast cancer in China. Lancet Oncol 2014, 15:e279-e289.
5. Couture J.F., Collazo E., Brunzelle J.S., Trievel R.C. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev 2005, 19:1455-1465.
6. Fang J., Feng Q., Ketel C.S., Wang H., Cao R., Xia L., et al. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr. Biol 2002, 12:1086-1099.
7. Beck D.B., Oda H., Shen S.S., Reinberg D. PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev 2012, 26:325-337.
8. Tardat M., Murr R., Herceg Z., Sardet C., Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J. Cell Biol 2007, 179:1413-1426.
9. Yin Y., Yu V.C., Zhu G., Chang D.C. SET8 plays a role in controlling G1/S transition by blocking lysine acetylation in histone through binding to H4 N-terminal tail. Cell Cycle 2008, 7:1423-1432.
10. Yu N., Huangyang P., Yang X., Han X., Yan R., Jia H., et al. microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8. J. Biol. Chem 2013, 288:19633-19642.
11. Guo F., Parker Kerrigan B.C., Yang D., Hu L., Shmulevich I., Sood A.K., et al. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J. Hematol. Oncol 2014, 7:19.
12. Song F., Zheng H., Liu B., Wei S., Dai H., Zhang L., et al. An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin. Cancer Res 2009, 15:6292-6300.
13. Chen K., Song F., Calin G.A., Wei Q., Hao X., Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008, 29:1306-1311.
14. Bentwich I., Avniel A., Karov Y., Aharonov R., Gilad S., Barad O., et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet 2005, 37:766-770.
15. Yang S.D., Cai Y.L., Jiang P., Li W., Tang J.X. Association of a miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and the TP53 codon 72 polymorphism with cervical cancer in the Chinese population. Asian Pac. J. Cancer Prev 2014, 15:6505-6510.
16. Yang S., Guo H., Wei B., Zhu S., Cai Y., Jiang P., et al. Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. Acta Biochim. Biophys. Sin. (Shanghai) 2014, 46:149-154.
17. Diao L., Su H., Wei G., Li T., Gao Y., Zhao G., et al. Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma. Tumori 2014, 100:553-558.
18. Ding C., Li R., Peng J., Li S., Guo Z. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer. Exp. Ther. Med 2012, 3:689-692.
19. Xu J., Yin Z., Gao W., Liu L., Yin Y., Liu P., et al. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS ONE 2013, 8:e77024.
20. Wang C., Guo Z., Wu C., Li Y., Kang S. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. Cancer Genet 2012, 205:373-376.
21. Guo Z., Wu C., Wang X., Wang C., Zhang R., Shan B. A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int. J. Cancer 2012, 131:1318-1322.
22. Zhang B.H., Pan X.P., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol 2007, 302:1-12.
23. Zhang L., Liu Y., Song F., Zheng H., Hu L., Lu H., et al. Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13653-13658.
24. Zheng H., Song F., Zhang L., Yang D., Ji P., Wang Y., et al. Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. Int. J. Oncol 2011, 38:1153-1161.
25. Liu B., Qu J., Xu F., Guo Y., Wang Y., Yu H., et al. MiR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget 2015, 6:9445-9456.
26. Song F., Yang D., Liu B., Guo Y., Zheng H., Li L., et al. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin. Cancer Res 2014, 20:878-889.
27. Zhai H., Song B., Xu X., Zhu W., Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 2013, 32:1570-1579.
28. Chen S., Li F., Chai H., Tao X., Wang H., Ji A. miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma. Biochem. Biophys. Res. Commun 2015, 464:500-505.
29. Li S., Xie Y., Zhang W., Gao J., Wang M., Zheng G., et al. Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness. J. Surg. Res 2015, 193:255-264.
30. Sun L.L., Wang J., Zhao Z.J., Liu N., Wang A.L., Ren H.Y., et al. Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2. Oncol. Rep 2014, 31:2085-2092.
31. Rice J.C., Nishioka K., Sarma K., Steward R., Reinberg D., Allis C.D. Mitotic-specific methylation of histone H4 Lys 20 follows increased PR-Set7 expression and its localization to mitotic chromosomes. Genes Dev 2002, 16:2225-2230.
32. Oda H., Okamoto I., Murphy N., Chu J., Price S.M., Shen M.M., et al. Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol. Cell. Biol 2009, 29:2278-2295.
33. Jorgensen S., Elvers I., Trelle M.B., Menzel T., Eskildsen M., Jensen O.N., et al. The histone methyltransferase SET8 is required for S-phase progression. J. Cell Biol 2007, 179:1337-1345.
34. Houston S.I., McManus K.J., Adams M.M., Sims J.K., Carpenter P.B., Hendzel M.J., et al. Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J. Biol. Chem 2008, 283:19478-19488.
35. Wu S., Wang W., Kong X., Congdon L.M., Yokomori K., Kirschner M.W., et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev 2010, 24:2531-2542.
36. Yang F., Sun L., Li Q., Han X., Lei L., Zhang H., et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 2012, 31:110-123.
37. Jorgensen S., Eskildsen M., Fugger K., Hansen L., Larsen M.S., Kousholt A.N., et al. SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation. J. Cell Biol 2011, 192:43-54.
38. Li Z., Nie F., Wang S., Li L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3116-3123.
39. Li Y., Sun L., Zhang Y., Wang D., Wang F., Liang J., et al. The histone modifications governing TFF1 transcription mediated by estrogen receptor. J. Biol. Chem 2011, 286:13925-13936.
40. Shi X.L., Guo Z.J., Wang X.L., Liu X.L., Shi G.F. SET8 expression is associated with overall survival in gastric cancer. Genet. Mol. Res 2015, 14:15609-15615.
41. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet 2012, 13:343-357.
42. Chi P., Allis C.D., Wang G.G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
43. Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 2007, 27:636-646.
44. Xi Y., Shalgi R., Fodstad O., Pilpel Y., Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin. Cancer Res 2006, 12:2014-2024.
45. Bartek J., Iggo R., Gannon J., Lane D.P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990, 5:893-899.
46. Norberg T., Klaar S., Karf G., Nordgren H., Holmberg L., Bergh J. Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort. Cancer Res 2001, 61:8317-8321.
47. Poelman S.M., Heimann R., Fleming G.F., Recant W.M., Conzen S.D. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur. J. Cancer 2004, 40:28-32.